Article

Angiosarcoma Complicating Systemic Sclerosis: A Case Report

Cutis. 2008 June;81(6):468-471

PDF Download

References

Mark RJ, Poen JC, Tran LM, et al. Angiosarcoma: a report of 67 patients and a review of the literature. Cancer. 1996;77:2400-2406.
Morgan MB, Swann M, Somach S, et al. Cutaneous angiosarcoma: a case series with prognostic correlation. J Am Acad Dermatol. 2004;50:867-874.
Holden CA, Spittle MF, Jones EW. Angiosarcoma of the face and scalp, prognosis and treatment. Cancer. 1987;59:1046-1057.
Haustein UF. Angiosarcoma of the face and scalp. Int J Dermatol. 1991;30:851-856.
Rossi S, Fletcher CD. Angiosarcoma arising in hemangioma/vascular malformation: report of four cases and review of the literature. Am J Surg Pathol. 2002;26:1319-1329.
Puizina-Ivic N, Bezic J, Marasovic D, et al. Angiosarcoma arising in sclerodermatous skin. Acta Dermatovenerol Alp Panonica Adriat. 2005;14:20-25.
Distler O, Distler JH, Scheid A, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res. 2004;95: 109-116.
Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol. 2005;26:587-595.
Reveille JD. Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Curr Rheumatol Rep. 2003;5:160-167.
Leandro MJ, Isenberg DA. Rheumatic diseases and malignancy—is there an association? Scand J Rheumatol. 2001;30:185-188.
Rosenthal AK, McLaughlin JK, Gridley G, et al. Incidence of cancer among patients with systemic sclerosis. Cancer. 1995;76:910-914.
Amo Y, Masuzawa M, Hamada Y, et al. Serum concentrations of vascular endothelial growth factor in angiosarcomas with and without p53 gene mutation. Acta Derm Venereol. 2002;82:373-374.
Arbiser JL, Larsson H, Claesson-Welsh L, et al. Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo. Am J Pathol. 2000;156:1469-1476.
Zietz C, Rössle M, Haas C, et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol. 1998;153:1425-1433.
Fata F, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86:2034-2037.
Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer. 2005;104:361-366.

References

Mark RJ, Poen JC, Tran LM, et al. Angiosarcoma: a report of 67 patients and a review of the literature. Cancer. 1996;77:2400-2406.
Morgan MB, Swann M, Somach S, et al. Cutaneous angiosarcoma: a case series with prognostic correlation. J Am Acad Dermatol. 2004;50:867-874.
Holden CA, Spittle MF, Jones EW. Angiosarcoma of the face and scalp, prognosis and treatment. Cancer. 1987;59:1046-1057.
Haustein UF. Angiosarcoma of the face and scalp. Int J Dermatol. 1991;30:851-856.
Rossi S, Fletcher CD. Angiosarcoma arising in hemangioma/vascular malformation: report of four cases and review of the literature. Am J Surg Pathol. 2002;26:1319-1329.
Puizina-Ivic N, Bezic J, Marasovic D, et al. Angiosarcoma arising in sclerodermatous skin. Acta Dermatovenerol Alp Panonica Adriat. 2005;14:20-25.
Distler O, Distler JH, Scheid A, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res. 2004;95: 109-116.
Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol. 2005;26:587-595.
Reveille JD. Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Curr Rheumatol Rep. 2003;5:160-167.
Leandro MJ, Isenberg DA. Rheumatic diseases and malignancy—is there an association? Scand J Rheumatol. 2001;30:185-188.
Rosenthal AK, McLaughlin JK, Gridley G, et al. Incidence of cancer among patients with systemic sclerosis. Cancer. 1995;76:910-914.
Amo Y, Masuzawa M, Hamada Y, et al. Serum concentrations of vascular endothelial growth factor in angiosarcomas with and without p53 gene mutation. Acta Derm Venereol. 2002;82:373-374.
Arbiser JL, Larsson H, Claesson-Welsh L, et al. Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo. Am J Pathol. 2000;156:1469-1476.
Zietz C, Rössle M, Haas C, et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol. 1998;153:1425-1433.
Fata F, O'Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86:2034-2037.
Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer. 2005;104:361-366.

Angiosarcoma Complicating Systemic Sclerosis: A Case Report

References

Pages

Recommended Reading